Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554229 · ClinicalTrials.gov registry record · Phase 3
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 896
- Enrollment target
NCT00554229 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 896 participants.
The verdict
NCT00554229, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 896 participants
- Enrollment target
Study Summary
Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases. * This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve survival compared with placebo. * ZD4054(Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer patients with bone metastases. * All patients participating in this clinical trial will receive existing standard prostate cancer treatments in addition to trial therapy. * Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour. * No patients will be deprived of standard prostate cancer therapy.
Interventions
- DRUG Placebo
- DRUG ZD4054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00554229
The ClinicalTrials.gov registry entry for NCT00554229 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 896 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00554229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00554229 about?
NCT00554229 is a clinical study titled "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases". Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases. * This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve survival compared wi...
What is the current status of trial NCT00554229?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 896 participants. The study started on 2007-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00554229?
The interventions under investigation include: Placebo (DRUG), ZD4054 (DRUG).
Who is sponsoring clinical trial NCT00554229?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.